AbbVie's Venetoclax Doesn't Meet Primary Endpoint for Higher-Risk Myelodysplastic Syndrome

 AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

The drugmaker said data from the trial doesn't impact any current approved indications for venetoclax.

Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group.

https://www.morningstar.com/news/dow-jones/202506164170/abbvies-venetoclax-doesnt-meet-primary-endpoint-in-trial-for-higher-risk-myelodysplastic-syndrome-treatment